Amorfix and BioMosaics collaborate to develop a blood test for liver cancer
The liver cancer blood test is based on antibodies to the biomarker Glypican-3 (GPC3), discovered by Dr. Jorge Filmus at Sunnybrook. The collaboration utilizes BioMosaics' expertise in the cancer biomarker area and the assay development capability at Amorfix. “Our expertise in developing highly sensitive blood assays is part of our core capabilities and we welcome the opportunity to apply our knowledge to achieve a blood test for the early detection of primary liver cancer,” said Dr. George Adams, CEO of Amorfix. Antibodies to GPC3 are sold worldwide by BioMosaics for use in pathology laboratories to confirm HCC, and GPC3 is widely accepted as an immunohistochemical biomarker of early HCC. “A robust and sensitive immunoassay for detection of GPC3 circulating in the bloodstream will facilitate monitoring and early detection of liver cancer in high-risk groups such as people with chronic hepatitis,” said Dr. Mark Allegretta, President of BioMosaics.
Under this commercial collaboration, BioMosaics will have the opportunity to market the new test directly, as well as through its existing distributors, and Amorfix will receive royalties on commercial product sales, as well as an option to manufacture the assay kits and reagents for global distribution.
Other news from the department science
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous